Warning: mkdir(): No space left on device in /www/wwwroot/zhenghe1718.com/func.php on line 127

Warning: file_put_contents(./cachefile_yuan/pkscc.com/cache/a2/d45e0/c8a90.html): failed to open stream: No such file or directory in /www/wwwroot/zhenghe1718.com/func.php on line 115
 HCI-2509(SP2509),ReversibleLSD1Inhibitor. M60160-2s|产品详情|进口橙子视频旧款采购网




  • 橙子视频app安卓下载,91橙子视频,橙子视频旧款,橙子视频在线官网

    订购信息
    上海橙子视频app安卓下载生物科技公司
    Tel:400-968-7988    021-33779008
    HCI-2509(SP2509),ReversibleLSD1Inhibitor.
    品牌:Xcessbio
    货号:M60160-2s
    规格:2 mg solid
    货期:

    HCI-2509(SP2509),ReversibleLSD1Inhibitor.

    商品详情 参考文献 相关资料
    Product Information
    Molecular Weight: 437.90
    Formula: C19H20ClN3O5S
    Purity: ≥98%
    CAS#: 1423715-09-6
    Solubility: DMSO up to 50 mM
    Chemical Name: (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide
    Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

    Biological Activity:


    HCI-2509 (also named as SP2509 or LSD1-C12) is a highly potent, specific, and reversible Lysine Specific Demethylase-1 (LSD1) inhibitor. It inhibits LSD1 in biochemical assay with an IC50 ~13 nM, and has no activity against monoamine oxidase proteins MAO-A and MAO-B (>300 µM). HCI-2509 is a non-competitive inhibitor to bind LSD1, changes its solution dynamics in a manner distinct from TCP. It has minimal inhibition of CYPs and hERG, shows cellular activity against several cancer cell lines including endometrial, breast, colorectal, pancreatic, and prostate cancer (IC50 ~0.3-2.5 µM). HCI-2509 displayed sing-agent efficacy in multiple xenograft models and had good PK/PD relationship by using tumor histone H3K4 and H3K9 methylation. HCI-2509 serves as a very useful chemical probe to study the target biology of LSD1.

    How to Use:


    In vitro: HCI-2509 was used at 1 µM in vitro.
    In vivo: HCI-2509 was administered through IP injection at 25-30 mg/kg once per day in xenografts models.

    Reference:

    • 1. Fiskus W, et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. (2014) Leukemia. 28(11):2155-64. 
    • 2. Sorna V, et al. High-Throughput Virtual Screening Identifies Novel N'-(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors. (2013) J Med Chem. 56(23):9496-508. 
    • 3. Wiles ET, et al. BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma. (2013) PLoS One. 8(3):e59369. 
    • 4. Bret J. Stephens, et al.: Activity of the LSD1 inhibitor HCI-2509 in ER-negative breast cancer cells. (2012) AACR Chicago. Abstract 1045. Cancer Research: April 15, 2012; Volume 72, Issue 8, Supplement 1.
    • 5. Emily R, et al. Inhibition of LSD1 disrupts global EWS/ETS transcriptional function in Ewing sarcoma. (2014) AACR San Diego. Abstract 3679. 

          
          


    Products are for research use only. Not for human use.

    • 关于橙子视频app安卓下载
    • 购物流程
    • 支付方式
    • 配送方式
    Copyright@ 2003-2026  进口橙子视频旧款采购网版权所有     

    BIOLEAF热搜   BIOLEAF91橙子视频   BIOLEAF ELISA   BIOLEAF橙子视频旧款   BIOLEAF品牌   BIOLEAF抗体   BIOLEAF耗材   BIOLEAF小仪器

    sitemap   细胞库查询   危险品图标

    本公司网站所展示销售的产品仅供科研!

             沪ICP备08023583号-6     
    产品咨询
    QQ扫码沟通
    在线客服
    服务电话
    400-968-7988
    扫码关注
    微信公众号二维码

    沪公网安备 31011202007338号

    网站地图